Avidity Partners Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Avidity Partners Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-320,000	Closed	-$22.5M	–	66
2024 Q3	$22.5M	Buy	+320,000	New	+$26.7M	1.15%	36
2023 Q2	–	Sell	-300,575	Closed	-$29.2M	–	99
2023 Q1	$29.2M	Buy	+300,575	New	+$31.2M	0.97%	37
2021 Q1	–	Sell	-992,900	Closed	-$87.1M	–	101
2020 Q4	$87.1M	Buy	+992,900	New	+$78.7M	2.83%	8
2020 Q2	–	Sell	-302,000	Closed	-$25.5M	–	61
2020 Q1	$25.5M	Buy	+302,000	New	+$26M	3.53%	5

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Avidity Partners Management's BMRN Position: Q4 2024 in Review

Avidity Partners Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 320,000 shares — an estimated $22.5M sold.

Avidity Partners Management first reported a position in BMRN in Q1 2020 and held it in 4 quarters. The position peaked at $87.1M in Q4 2020. 546 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

Avidity Partners Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Avidity Partners Management sold 320,000 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $22.5M.
Avidity Partners Management first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 4 quarters.
Avidity Partners Management's BioMarin Pharmaceuticals position peaked at $87.1M in Q4 2020.
546 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.